Brief: Aytu Biopharma Inc - Announces Strategic Shift To Focus On Commercial Operations And Indefinite Suspension Of Clinical Development Programs

Aytu Biopharma

13/10/2022 13:17

Oct 13 (Reuters) - Aytu Biopharma Inc  AYTU.O :
    * AYTU BIOPHARMA INC - ANNOUNCES STRATEGIC SHIFT TO FOCUS ON
COMMERCIAL OPERATIONS AND INDEFINITE SUSPENSION OF CLINICAL
DEVELOPMENT PROGRAMS
    * AYTU BIOPHARMA INC - INDEFINITELY SUSPENDING CLINICAL
DEVELOPMENT AND REMOVING EXPENSES RELATED TO AR101/ENZASTAURIN,
HEALIGHT, AND NT0502
    * AYTU BIOPHARMA INC - EXPECTING TO GENERATE POSITIVE
QUARTERLY
ADJUSTED EBITDA IN THE FIRST HALF OF CALENDAR 2023
    * AYTU BIOPHARMA INC - EXPECTED FUTURE CLINICAL DEVELOPMENT
SAVINGS OF MORE THAN $20 MILLION

Further company coverage:  AYTU.O 
 ((Reuters.Briefs@thomsonreuters.com;))